Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

York University

$40,000.00

Role of somatostatin signalling on pancreatic islet function and energy homeostasis

FY 2020-21

Summary
For over 90 years, the study of the endocrine pancreas has mainly been limited to insulin and glucagon. However, the intact pancreatic islet acts as a complete organ system with five different cell types (, , , , ) and a dedicated vasculature and neural supply. Within the islet, the delta () cell secretes the inhibitory hormone somatostatin (SST) that binds to various G-coupled protein SST receptors (SSTR1-5) found on the other cell types. SSTR1/2 are expressed in a number of other tissues that impact energy metabolism, including the adipose tissue, liver and skeletal muscle, but the role of these receptors on metabolism is unclear. We have discovered that SST release from pancreatic islets is impacted during low, normal and high blood glucose levels and that SST levels dramatically influences the release of glucagon during hypoglycemia. This suggests that SST plays a critical regulatory role in the regulatory defence against hypoglycemia. However, it is still unclear what impact SST signalling has in the release of various islet hormones including insulin, amylin, glucagon, pancreatic peptide and ghrelin under various conditions including exercise, mild hyperglycemia, mild hypoglycemia and euglycaemia. This Discovery Grant aims to elucidate the local cross-talk among islet cells, with an emphasis on SST signalling during so called normal' physiology. Using primarily in vivo approaches (rodent models) and a library of newly developed SSTR agonists and antagonists, we will elucidate the normal mechanisms for SST's tight regulation of islet function to maintain energy homeostasis. Using novel pharmacological agents and new in vivo approaches, this research will focus on the potential direct role of SST signalling in regulating islet hormone release and substrate metabolism in liver, skeletal muscle and adipose tissue. Aim 1 will focus on using various agonists and antagonists, chosen for their specificity for each of the five receptor subtypes, to determine how SST signalling impacts islet function and hormone release (insulin, glucagon, amylin, pancreatic polypeptide, ghrelin and SST) into the portal circulation using under basal conditions (fasting, rested state) and under various stimulated conditions (feeding, exercise). Aim 2 will examine the potential triggers of SST release in vivo<span style="font-family: Camb
Program
Discovery Grants Program - Individual
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2018-05933
Name nom
Riddell, Michael
Department département
Kinesiology and Health Science
Organization id
38
Institution établissement
York University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2018
Award amount
40000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1502
Committee name en
Biological Systems and Functions
Committee name fr
Systèmes et fonctions biologiques
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5504
Research subject group en
Animal biology
Research subject group fr
Biologie animale
Research subject en
Animal physiology and metabolism
Research subject fr
Physiologie et métabolisme des animaux
Installment
inst:3-5
Partie
3
Nb partie
5
Application title
Role of somatostatin signalling on pancreatic islet function and energy homeostasis
Keyword
NSERC
Application summary
For over 90 years, the study of the endocrine pancreas has mainly been limited to insulin and glucagon. However, the intact pancreatic islet acts as a complete organ system with five different cell types (, , , , ) and a dedicated vasculature and neural supply. Within the islet, the delta () cell secretes the inhibitory hormone somatostatin (SST) that binds to various G-coupled protein SST receptors (SSTR1-5) found on the other cell types. SSTR1/2 are expressed in a number of other tissues that impact energy metabolism, including the adipose tissue, liver and skeletal muscle, but the role of these receptors on metabolism is unclear. We have discovered that SST release from pancreatic islets is impacted during low, normal and high blood glucose levels and that SST levels dramatically influences the release of glucagon during hypoglycemia. This suggests that SST plays a critical regulatory role in the regulatory defence against hypoglycemia. However, it is still unclear what impact SST signalling has in the release of various islet hormones including insulin, amylin, glucagon, pancreatic peptide and ghrelin under various conditions including exercise, mild hyperglycemia, mild hypoglycemia and euglycaemia. This Discovery Grant aims to elucidate the local cross-talk among islet cells, with an emphasis on SST signalling during so called normal' physiology. Using primarily in vivo approaches (rodent models) and a library of newly developed SSTR agonists and antagonists, we will elucidate the normal mechanisms for SST's tight regulation of islet function to maintain energy homeostasis. Using novel pharmacological agents and new in vivo approaches, this research will focus on the potential direct role of SST signalling in regulating islet hormone release and substrate metabolism in liver, skeletal muscle and adipose tissue. Aim 1 will focus on using various agonists and antagonists, chosen for their specificity for each of the five receptor subtypes, to determine how SST signalling impacts islet function and hormone release (insulin, glucagon, amylin, pancreatic polypeptide, ghrelin and SST) into the portal circulation using under basal conditions (fasting, rested state) and under various stimulated conditions (feeding, exercise). Aim 2 will examine the potential triggers of SST release in vivo<span style="font-family: Camb